CeriBell (NASDAQ:CBLL) CFO Sells $16,300.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 652 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $25.00, for a total value of $16,300.00. Following the completion of the transaction, the chief financial officer directly owned 146,600 shares of the company’s stock, valued at $3,665,000. The trade was a 0.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Scott Blumberg also recently made the following trade(s):

• On Friday, August 21st, Scott Blumberg sold 1,521 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $36,534.42.
• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total value of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Price Performance

CBLL stock traded up $0.15 during mid-day trading on Friday, reaching $24.72. 220,005 shares of the company traded hands, compared to its average volume of 343,502. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The company has a market capitalization of $948.70 million, a P/E ratio of -14.05 and a beta of 0.95. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.33. The company has a fifty day moving average price of $20.57 and a 200-day moving average price of $19.46.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 28th. Canaccord Genuity Group increased their price objective on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. BTIG Research lifted their price objective on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Raymond James Financial restated a “strong-buy” rating and issued a $29.00 target price on shares of CeriBell in a research note on Thursday. Finally, Barclays raised CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.40.

Hedge Funds Weigh In On CeriBell

Institutional investors have recently made changes to their positions in the stock. TimesSquare Capital Management LLC purchased a new position in CeriBell in the second quarter worth $15,182,000. Royce & Associates LP purchased a new stake in CeriBell during the fourth quarter valued at about $11,695,000. Bank of New York Mellon Corp purchased a new stake in CeriBell during the second quarter valued at about $17,437,000. BlackRock Inc. bought a new stake in CeriBell during the second quarter worth about $37,657,000. Finally, Deutsche Bank AG purchased a new position in shares of CeriBell in the 2nd quarter worth about $1,742,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.